Omeros Corp OMER:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:54 PM EDT
2.92quote price arrow down-0.12 (-3.88%)
Volume
4,278
Close
3.04quote price arrow down-0.05 (-1.62%)
Volume
240,924
52 week range
0.92 - 7.80
Loading...
  • Open3.09
  • Day High3.12
  • Day Low3.03
  • Prev Close3.09
  • 52 Week High7.80
  • 52 Week High Date06/05/23
  • 52 Week Low0.92
  • 52 Week Low Date10/16/23

Key Stats

  • Market Cap176.146M
  • Shares Out57.94M
  • 10 Day Average Volume0.36M
  • Dividend-
  • Dividend Yield-
  • Beta1.34
  • YTD % Change-7.03

KEY STATS

  • Open3.09
  • Day High3.12
  • Day Low3.03
  • Prev Close3.09
  • 52 Week High7.80
  • 52 Week High Date06/05/23
  • 52 Week Low0.92
  • 52 Week Low Date10/16/23
  • Market Cap176.146M
  • Shares Out57.94M
  • 10 Day Average Volume0.36M
  • Dividend-
  • Dividend Yield-
  • Beta1.34
  • YTD % Change-7.03

RATIOS/PROFITABILITY

  • EPS (TTM)-2.79
  • P/E (TTM)-1.09
  • Fwd P/E (NTM)-1.35
  • EBITDA (TTM)-163.61M
  • ROE (TTM)-576.33%
  • Revenue (TTM)-
  • Gross Margin (TTM)98.89%
  • Net Margin (TTM)-136.61%
  • Debt To Equity (MRQ)-1,354.04%

EVENTS

  • Earnings Date05/07/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Omeros Corp

 

Profile

MORE
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for...
Gregory Demopulos M.D.
Chairman of the Board, President, Chief Executive Officer
Michael Jacobsen
Vice President - Finance, Chief Accounting Officer, Treasurer
Peter Cancelmo J.D.
Vice President, General Counsel, Secretary
Mariana Dimitrova Ph.D.
Vice President - Chemistry, Manufacturing and Controls
Tina Quinton J.D.
Vice President - Patents
Address
201 Elliott Avenue West
Seattle, WA
98119
United States

Top Peers

SYMBOLLASTCHG%CHG
SCPH
scPharmaceuticals Inc
4.50-0.11-2.39%
RLMD
Relmada Therapeutics Inc
3.86-0.05-1.28%
MDWD
Mediwound Ltd
17.59+1.18+7.19%
CRMD
CorMedix Inc
5.33-0.12-2.20%
VYNE
Vyne Therapeutics Inc
2.57+0.25+10.78%